You are leaving Smmttx.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible
for its contents.

Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.

To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.

Clinical Trials

Ivonescimab (SMT112)

Summit Clinical Trials for Ivonescimab (SMT112)

 

Ivonescimab: Most Advanced PD-1/VEGF Bispecific Antibody in the U.S. & EU.*
Brings two validated mechanisms in oncology1,2,3 into ONE novel tetravalent molecule.

 

Phase 3 Study: NCT05184712
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment.
Phase 3 Study: NCT05899608
A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer.

 

For Information on the Ivonescimab MOA

Click here

For additional information on the HARMONi or the HARMONi-3 clinical trials, please visit clinicaltrials.gov or contact medinfo@smmttx.com

 

1. Manegold et al., (2016); JTO 12:2.194-207.; 2. Pardoll, Drew M. (2012) Nature Reviews Cancer vol. 12,4 :252-64.; 3. Tamura et al., (2020) Med Oncol 37:2, 10.1007.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority.

*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”).